Adverum Biotechnologies (ADVM)
(Real Time Quote from BATS)
$7.87 USD
+0.09 (1.16%)
Updated Jul 11, 2024 02:10 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
ADVM 7.87 +0.09(1.16%)
Will ADVM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ADVM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ADVM
Down -19.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?
ADVM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Absci (ABSI) to Report Q1 Earnings: Here's What to Expect
PetIQ (PETQ) Gears Up to Report Q1 Earnings: What's in Store?
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
Other News for ADVM
Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting
Adverum Biotechnologies initiated with bullish view at Oppenheimer, here's why
Adverum Biotechnologies to Participate in TD Cowen’s Genetic Medicines & RNA Summit
Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of Directors
Adverum Biotechnologies appoints Ozden as CMO, Kiss to board of directors